{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:37:58Z","timestamp":1784205478148,"version":"3.55.0"},"reference-count":48,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The management of hidradenitis suppurativa (HS) in elderly patients presents unique challenges due to its chronic inflammatory nature, heterogeneous clinical presentation and comorbidities. While HS typically affects the anogenital and intertriginous regions, elderly patients may exhibit atypical features such as the involvement of the neck, mammary area and gluteal region. The prevalence of HS in the elderly population is lower and the average age of disease onset is higher than in patients under 65. In contrast, it is unclear whether HS in the elderly has different clinical features. The elderly frequently present multiple comorbidities, including obesity, diabetes, and heart disease, which further complicate management decisions. Therapeutic interventions must consider the frailty and increased risk of multimorbidity and adverse events in elderly patients. While systemic antibiotics remain a mainstay of HS treatment, biologic agents such as TNF\u03b1 inhibitors and secukinumab offer promising options for refractory cases. However, their safety and efficacy in elderly patients, particularly those with multiple comorbidities, require careful consideration. A comprehensive approach to managing HS in elderly patients involves not only pharmacological interventions but also lifestyle modifications and surgical options where appropriate. Multidisciplinary collaboration between dermatologists, geriatricians and other specialists is essential for tailoring treatment strategies and optimizing long-term outcomes and quality of life in special population.<\/jats:p>","DOI":"10.3390\/medicina60091465","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:53:11Z","timestamp":1725623591000},"page":"1465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes\u2014A Review of the Literature"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7997-1784","authenticated-orcid":false,"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Brescia","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-637X","authenticated-orcid":false,"given":"Teresa","family":"Battista","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.clindermatol.2023.08.020","article-title":"Epidemiology of hidradenitis suppurativa","volume":"41","year":"2023","journal-title":"Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bjd\/ljad317","article-title":"Hidradenitis suppurativa tarda: Defining an understudied elderly population","volume":"190","author":"Koerts","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: A population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2021.02.075","article-title":"Late-onset hidradenitis suppurativa: A cluster analysis of the National Italian Registry IRHIS","volume":"85","author":"Cazzaniga","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1759720X19895488","DOI":"10.1177\/1759720X19895488","article-title":"Hidradenitis suppurativa: Infection, autoimmunity, or both?","volume":"11","author":"Constantinou","year":"2019","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2022.5390","article-title":"Hidradenitis Suppurativa in Older Adults","volume":"159","author":"Blum","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2016.07.041","article-title":"The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study","volume":"76","author":"Denny","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.2174\/0929867326666190717152739","article-title":"From Healthy Aging to Frailty: In Search of the Underlying Mechanisms","volume":"26","author":"Brivio","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","first-page":"114","article-title":"What is hidradenitis suppurativa?","volume":"63","author":"Lee","year":"2017","journal-title":"Can. Fam. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., and Fabbrocini, G. (2021). Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 10.","DOI":"10.3390\/cells10082094"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jamadermatol.2019.0478","article-title":"Distribution of Self-reported Hidradenitis Suppurativa Age at Onset","volume":"155","author":"Naik","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2014.11.017","article-title":"Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement","volume":"72","author":"Deckers","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ljad378","DOI":"10.1093\/bjd\/ljad378","article-title":"Hidradenitis suppurativa in the elderly: New insights","volume":"2023","author":"White","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bpobgyn.2014.07.012","article-title":"Hidradenitis suppurativa","volume":"28","author":"Margesson","year":"2014","journal-title":"Best. Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/bjd\/ljac121","article-title":"Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa","volume":"188","author":"Jiang","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/bjd\/ljad411","article-title":"Elderly male patients with hidradenitis suppurativa have more severe disease independent of disease duration","volume":"190","author":"Nielsen","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: Clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study","volume":"17","author":"Martora","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjd.19863","article-title":"Adalimumab and infliximab survival in patients with hidradenitis suppurativa: A daily practice cohort study","volume":"185","author":"Prens","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jdcr.2022.03.008","article-title":"Hidradenitis suppurativa flares following COVID-19 vaccination: A case series","volume":"23","author":"Martora","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000521712","article-title":"A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?","volume":"8","author":"Martora","year":"2022","journal-title":"Skin. Appendage Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ced.15306","article-title":"Management of patients with hidradenitis suppurativa during COVID-19 vaccination: An experience from southern Italy. Comment on: \u2018Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Molinelli, E., Gioacchini, H., Sapigni, C., Diotallevi, F., Brisigotti, V., Rizzetto, G., Offidani, A., and Simonetti, O. (2023). New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098428"},{"key":"ref_27","first-page":"e449","article-title":"Hidradenitis suppurativa: Pathogenesis, clinical presentation, epidemiology, and comorbid associations","volume":"60","author":"Ahmed","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: An update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez, T., Diaz-Calvillo, P., Rodriguez-Pozo, J.A., Cuenca-Barrales, C., Martinez-Lopez, A., Arias-Santiago, S., and Molina-Leyva, A. (2021). The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18136709"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2815","article-title":"Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa","volume":"98","author":"Matusiak","year":"2018","journal-title":"Acta Derm.-Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","article-title":"Drug Survival of Biologics in Patients with Hidradenitis Suppurativa","volume":"158","author":"Ring","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2147\/CCID.S418748","article-title":"Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data","volume":"16","author":"Martora","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tsai, Y.C., Hung, C.Y., and Tsai, T.F. (2023). Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051351"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Huang, C.H., Huang, I.H., Tai, C.C., and Chi, C.C. (2022). Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061303"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Martora, F., Scalvenzi, M., Ruggiero, A., Potestio, L., Battista, T., and Megna, M. (2023). Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina, 59.","DOI":"10.3390\/medicina59040801"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/ced.15291","article-title":"Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: Comment on \u2018Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Markota \u010cagalj, A., Marinovi\u0107, B., and Bukvi\u0107 Mokos, Z. (2022). New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073753"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Goldust","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2020.1728253","article-title":"Safety concerns with current treatments for psoriasis in the elderly","volume":"19","author":"Caiazzo","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_42","first-page":"846","article-title":"Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis","volume":"14","author":"Garber","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jdv.15139","article-title":"Elderly psoriatic patients under biological therapies: An Italian experience","volume":"33","author":"Ricceri","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for Psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol. Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa: Advances in Diagnosis and Treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_47","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa\u2014Short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"J. Der Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: A practical framework for treatment optimization\u2014Systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/9\/1465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:50:00Z","timestamp":1760111400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/9\/1465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["medicina60091465"],"URL":"https:\/\/doi.org\/10.3390\/medicina60091465","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}